The alzheimer’s disease treatment market size has grown strongly in recent years. It will grow from $5.93 billion in 2023 to $6.41 billion in 2024 at a compound annual growth rate (CAGR) of 8.2%. The growth observed during the historical period in Alzheimer's disease treatment can be attributed to factors such as advancements in research and understanding of the disease, approvals of new drugs and their entry into the market, government initiatives and funding for Alzheimer's research, and increased public awareness and education about the condition.
The alzheimer’s disease treatment market size is expected to see strong growth in the next few years. It will grow to $8.35 billion in 2028 at a compound annual growth rate (CAGR) of 6.8%. The anticipated growth in the forecast period in Alzheimer's disease treatment can be attributed to various factors, including the adoption of precision medicine approaches, an increase in healthcare expenditure, the global burden of the disease, advancements in genetic and biomarker research, and the growth of emerging markets. Major trends expected in the forecast period encompass biotechnological breakthroughs, technological innovations, the integration of digital health technologies, a focus on precision medicine approaches, modulation of neuroinflammation, and increased collaborations and partnerships in the field.
The rising incidence of Alzheimer's disease stands as a significant driver fueling the expansion of the Alzheimer’s disease treatment market. Alzheimer's, the most prevalent form of dementia, is anticipated to witness a notable increase in cases, particularly in the geriatric population. Projections from the USA Alzheimer's Association indicate a projected rise of at least 14% in Alzheimer’s patients across all US states by 2025, primarily attributed to the aging population. Globally, new cases of Alzheimer’s are expected to surge by 35% to 615,000 by 2030 and further increase by 110% to 959,000 by 2050. Consequently, the escalating prevalence of Alzheimer’s disease is anticipated to stimulate the demand, fostering the growth of the global Alzheimer’s disease treatment market.
Government initiatives are poised to be a key driver propelling the Alzheimer's disease treatment market forward. Government initiatives, encompassing plans and actions undertaken by governments to address specific health issues, play a crucial role in Alzheimer's disease treatment. These initiatives involve funding research projects and clinical trials for new drugs and treatments. An example is the National Institutes of Health (NIH), a prominent US-based biomedical and public health research agency, which witnessed an increase in spending on Alzheimer's and dementia research funding. In March 2022, funding escalated by $289 million, reaching a total of $3.5 billion. Consequently, government initiatives contribute significantly to steering the growth of the Alzheimer's disease treatment market.
The market encounters limitations due to the absence of definitive diagnostic techniques for Alzheimer’s disease (AD). Diagnosing AD lacks a singular, conclusive test such as a blood test, brain scan, or physical exam. Distinguishing AD symptoms from those of other conditions that produce dementia symptoms complicates the diagnostic process. Neurologists, neuropsychologists, geriatricians, and geriatric psychiatrists rely on various approaches for diagnosis, yet the lack of a single diagnostic test leads to delayed diagnosis. The absence of efficient and prompt diagnostic tools for AD acts as a hindrance, resulting in fewer diagnosed cases and reduced consumption of AD drugs, thereby limiting market growth.
An emerging trend in the Alzheimer's disease (AD) treatment market is the escalation in research and development (R&D) investments and collaborations, driven by emerging treatment technologies. The Alzheimer's Association plays a pivotal role in funding researchers exploring innovative therapeutic approaches and advocates for increased government funding for Alzheimer's studies. Technologies such as β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors and anti-amyloid inhibitors are gaining prominence in the AD market. Key players, including Comentis and Astellas, collaborate to explore BACE inhibitors, while various manufacturing firms such as AC Immune, Adamas Pharmaceuticals, INmune Bio, Intra-Cellular Therapies, and vTv Therapeutics focus on R&D investments, advancing research molecules in clinical trials to pioneer breakthroughs in Alzheimer's disease treatment.
Major companies in the Alzheimer's disease treatment market are concentrating on developing innovative products such as assay kits to offer reliable services. Assay kits, comprised of reagents and materials for specific analytical tests, measure specific analytes. For example, Sysmex Corporation, a Japan-based healthcare company, launched the HISCL β-Amyloid 1-42 Assay Kit and the HISCL β-Amyloid 1-40 Assay Kit in June 2023. These products measure Aβ levels in blood, aiding in identifying Aβ accumulation in the brain, a hallmark of Alzheimer's disease. Sysmex's Automated Immunoassay System HISCL-5000/HISCL-800 facilitates the identification of brain Aβ accumulation, benefiting patients with suspected Aβ accumulation by alleviating financial, emotional, and physical burdens.
In February 2023, Lantheus Holdings Inc., a US-based provider of diagnostic imaging agents, acquired Cerveau Technologies, Inc., a move that is expected to expand Lantheus' imaging portfolio into Alzheimer’s disease. Cerveau Technologies, Inc., based in the US, is known for providing information and technology to researchers and clinicians, aligning with Lantheus' vision to broaden its footprint in Alzheimer's disease imaging.
Major companies operating in the alzheimer’s disease treatment market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Merck Sharp & Dohme Corp., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., UCB S.A., Eisai Co. Ltd., Forest Laboratories LLC, Ono Pharmaceutical Co. Ltd., H. Lundbeck A/S, Allergan PLC, Merz Pharma GmbH & Co. KGaA, Luye Pharma Group, Avanir Pharmaceuticals Inc., Denali Therapeutics Inc., Athira Pharma Inc., ProMIS Neurosciences Inc., AC Immune SA, vTv Therapeutics Inc., AB Science SA, TauRx Pharmaceuticals Ltd., Alzheon Inc. North America is the largest region in the alzheimer's disease treatment market in 2023. Middle East is expected to be the fastest growing region in the alzheimer’s disease treatment market share during the forecast period. The regions covered in the alzheimer’s disease treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The main types of drugs in Alzheimer's disease treatment include cholinesterase inhibitors and NMDA receptor antagonists. Cholinesterase inhibitors, also known as acetylcholinesterase inhibitors, belong to a class of drugs that work to prevent the normal breakdown of acetylcholine. Different drug classes within Alzheimer's disease treatment encompass cholinergic, memantine, combined drugs, AChE inhibitors, and immunoglobulins, involving various therapeutic approaches such as cholinesterase inhibitors, NMDA receptor antagonists, and other therapeutic methods.
The alzheimer’s disease treatment market research report is one of a series of new reports that provides alzheimer’s disease treatment market statistics, including alzheimer’s disease treatment industry global market size, regional shares, competitors with an alzheimer’s disease treatment market share, detailed Alzheimer’s disease treatment market segments, market trends and opportunities, and any further data you may need to thrive in the alzheimer’s disease treatment industry. This alzheimer’s disease treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The countries covered in the alzheimer’s disease treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The alzheimer’s disease treatment market includes revenues earned by entities by temporarily improve symptoms of memory loss and problems with thinking and reasoning. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The alzheimer’s disease treatment market size is expected to see strong growth in the next few years. It will grow to $8.35 billion in 2028 at a compound annual growth rate (CAGR) of 6.8%. The anticipated growth in the forecast period in Alzheimer's disease treatment can be attributed to various factors, including the adoption of precision medicine approaches, an increase in healthcare expenditure, the global burden of the disease, advancements in genetic and biomarker research, and the growth of emerging markets. Major trends expected in the forecast period encompass biotechnological breakthroughs, technological innovations, the integration of digital health technologies, a focus on precision medicine approaches, modulation of neuroinflammation, and increased collaborations and partnerships in the field.
The rising incidence of Alzheimer's disease stands as a significant driver fueling the expansion of the Alzheimer’s disease treatment market. Alzheimer's, the most prevalent form of dementia, is anticipated to witness a notable increase in cases, particularly in the geriatric population. Projections from the USA Alzheimer's Association indicate a projected rise of at least 14% in Alzheimer’s patients across all US states by 2025, primarily attributed to the aging population. Globally, new cases of Alzheimer’s are expected to surge by 35% to 615,000 by 2030 and further increase by 110% to 959,000 by 2050. Consequently, the escalating prevalence of Alzheimer’s disease is anticipated to stimulate the demand, fostering the growth of the global Alzheimer’s disease treatment market.
Government initiatives are poised to be a key driver propelling the Alzheimer's disease treatment market forward. Government initiatives, encompassing plans and actions undertaken by governments to address specific health issues, play a crucial role in Alzheimer's disease treatment. These initiatives involve funding research projects and clinical trials for new drugs and treatments. An example is the National Institutes of Health (NIH), a prominent US-based biomedical and public health research agency, which witnessed an increase in spending on Alzheimer's and dementia research funding. In March 2022, funding escalated by $289 million, reaching a total of $3.5 billion. Consequently, government initiatives contribute significantly to steering the growth of the Alzheimer's disease treatment market.
The market encounters limitations due to the absence of definitive diagnostic techniques for Alzheimer’s disease (AD). Diagnosing AD lacks a singular, conclusive test such as a blood test, brain scan, or physical exam. Distinguishing AD symptoms from those of other conditions that produce dementia symptoms complicates the diagnostic process. Neurologists, neuropsychologists, geriatricians, and geriatric psychiatrists rely on various approaches for diagnosis, yet the lack of a single diagnostic test leads to delayed diagnosis. The absence of efficient and prompt diagnostic tools for AD acts as a hindrance, resulting in fewer diagnosed cases and reduced consumption of AD drugs, thereby limiting market growth.
An emerging trend in the Alzheimer's disease (AD) treatment market is the escalation in research and development (R&D) investments and collaborations, driven by emerging treatment technologies. The Alzheimer's Association plays a pivotal role in funding researchers exploring innovative therapeutic approaches and advocates for increased government funding for Alzheimer's studies. Technologies such as β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors and anti-amyloid inhibitors are gaining prominence in the AD market. Key players, including Comentis and Astellas, collaborate to explore BACE inhibitors, while various manufacturing firms such as AC Immune, Adamas Pharmaceuticals, INmune Bio, Intra-Cellular Therapies, and vTv Therapeutics focus on R&D investments, advancing research molecules in clinical trials to pioneer breakthroughs in Alzheimer's disease treatment.
Major companies in the Alzheimer's disease treatment market are concentrating on developing innovative products such as assay kits to offer reliable services. Assay kits, comprised of reagents and materials for specific analytical tests, measure specific analytes. For example, Sysmex Corporation, a Japan-based healthcare company, launched the HISCL β-Amyloid 1-42 Assay Kit and the HISCL β-Amyloid 1-40 Assay Kit in June 2023. These products measure Aβ levels in blood, aiding in identifying Aβ accumulation in the brain, a hallmark of Alzheimer's disease. Sysmex's Automated Immunoassay System HISCL-5000/HISCL-800 facilitates the identification of brain Aβ accumulation, benefiting patients with suspected Aβ accumulation by alleviating financial, emotional, and physical burdens.
In February 2023, Lantheus Holdings Inc., a US-based provider of diagnostic imaging agents, acquired Cerveau Technologies, Inc., a move that is expected to expand Lantheus' imaging portfolio into Alzheimer’s disease. Cerveau Technologies, Inc., based in the US, is known for providing information and technology to researchers and clinicians, aligning with Lantheus' vision to broaden its footprint in Alzheimer's disease imaging.
Major companies operating in the alzheimer’s disease treatment market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Merck Sharp & Dohme Corp., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., UCB S.A., Eisai Co. Ltd., Forest Laboratories LLC, Ono Pharmaceutical Co. Ltd., H. Lundbeck A/S, Allergan PLC, Merz Pharma GmbH & Co. KGaA, Luye Pharma Group, Avanir Pharmaceuticals Inc., Denali Therapeutics Inc., Athira Pharma Inc., ProMIS Neurosciences Inc., AC Immune SA, vTv Therapeutics Inc., AB Science SA, TauRx Pharmaceuticals Ltd., Alzheon Inc. North America is the largest region in the alzheimer's disease treatment market in 2023. Middle East is expected to be the fastest growing region in the alzheimer’s disease treatment market share during the forecast period. The regions covered in the alzheimer’s disease treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The main types of drugs in Alzheimer's disease treatment include cholinesterase inhibitors and NMDA receptor antagonists. Cholinesterase inhibitors, also known as acetylcholinesterase inhibitors, belong to a class of drugs that work to prevent the normal breakdown of acetylcholine. Different drug classes within Alzheimer's disease treatment encompass cholinergic, memantine, combined drugs, AChE inhibitors, and immunoglobulins, involving various therapeutic approaches such as cholinesterase inhibitors, NMDA receptor antagonists, and other therapeutic methods.
The alzheimer’s disease treatment market research report is one of a series of new reports that provides alzheimer’s disease treatment market statistics, including alzheimer’s disease treatment industry global market size, regional shares, competitors with an alzheimer’s disease treatment market share, detailed Alzheimer’s disease treatment market segments, market trends and opportunities, and any further data you may need to thrive in the alzheimer’s disease treatment industry. This alzheimer’s disease treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The countries covered in the alzheimer’s disease treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The alzheimer’s disease treatment market includes revenues earned by entities by temporarily improve symptoms of memory loss and problems with thinking and reasoning. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Alzheimer’s Disease Treatment Market Characteristics3. Alzheimer’s Disease Treatment Market Trends and Strategies32. Global Alzheimer’s Disease Treatment Market Competitive Benchmarking33. Global Alzheimer’s Disease Treatment Market Competitive Dashboard34. Key Mergers and Acquisitions in the Alzheimer’s Disease Treatment Market
4. Alzheimer’s Disease Treatment Market - Macro Economic Scenario
5. Global Alzheimer’s Disease Treatment Market Size and Growth
6. Alzheimer’s Disease Treatment Market Segmentation
7. Alzheimer’s Disease Treatment Market Regional and Country Analysis
8. Asia-Pacific Alzheimer’s Disease Treatment Market
9. China Alzheimer’s Disease Treatment Market
10. India Alzheimer’s Disease Treatment Market
11. Japan Alzheimer’s Disease Treatment Market
12. Australia Alzheimer’s Disease Treatment Market
13. Indonesia Alzheimer’s Disease Treatment Market
14. South Korea Alzheimer’s Disease Treatment Market
15. Western Europe Alzheimer’s Disease Treatment Market
16. UK Alzheimer’s Disease Treatment Market
17. Germany Alzheimer’s Disease Treatment Market
18. France Alzheimer’s Disease Treatment Market
19. Italy Alzheimer’s Disease Treatment Market
20. Spain Alzheimer’s Disease Treatment Market
21. Eastern Europe Alzheimer’s Disease Treatment Market
22. Russia Alzheimer’s Disease Treatment Market
23. North America Alzheimer’s Disease Treatment Market
24. USA Alzheimer’s Disease Treatment Market
25. Canada Alzheimer’s Disease Treatment Market
26. South America Alzheimer’s Disease Treatment Market
27. Brazil Alzheimer’s Disease Treatment Market
28. Middle East Alzheimer’s Disease Treatment Market
29. Africa Alzheimer’s Disease Treatment Market
30. Alzheimer’s Disease Treatment Market Competitive Landscape and Company Profiles
31. Alzheimer’s Disease Treatment Market Other Major and Innovative Companies
35. Alzheimer’s Disease Treatment Market Future Outlook and Potential Analysis
36. Appendix
Executive Summary
Alzheimer’s Disease Treatment Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on alzheimer’s disease treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
- Assess the Russia-Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis.
- Report will be updated with the latest data and delivered to you with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for alzheimer’s disease treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
- The impact of higher inflation in many countries and the resulting spike in interest rates.
- The continued but declining impact of COVID-19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Report Scope
Markets Covered:1) By Drug Class: Cholinergic; Memantine; Combined Drug; AChE inhibitors; Immunoglobulins
2) By Drug Type: Cholinesterase Inhibitors; NMDA Receptor Antagonists
3) By Therapeutics: Cholinesterase Inhibitors; NMDA Receptor Antagonists; Other Therapeutics
Key Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; AbbVie Inc.; Bayer AG; Novartis AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes
Delivery Format: PDF, Word and Excel Data Dashboard
Companies Mentioned
- Pfizer Inc.
- F. Hoffmann-La Roche Ltd.
- AbbVie Inc.
- Bayer AG
- Novartis AG
- Bristol-Myers Squibb Company
- AstraZeneca plc
- Merck Sharp & Dohme Corp.
- Takeda Pharmaceutical Company Limited
- Eli Lilly and Company
- Amgen Inc.
- Teva Pharmaceutical Industries Ltd.
- Biogen Inc.
- UCB S.A.
- Eisai Co. Ltd.
- Forest Laboratories LLC
- Ono Pharmaceutical Co. Ltd.
- H. Lundbeck A/S
- Allergan plc
- Merz Pharma GmbH & Co. KGaA
- Luye Pharma Group
- Avanir Pharmaceuticals Inc.
- Denali Therapeutics Inc.
- Athira Pharma Inc.
- ProMIS Neurosciences Inc.
- AC Immune SA
- vTv Therapeutics Inc.
- AB Science SA
- TauRx Pharmaceuticals Ltd.
- Alzheon Inc.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2024 |
| Forecast Period | 2024 - 2028 |
| Estimated Market Value ( USD | $ 6.41 Billion |
| Forecasted Market Value ( USD | $ 8.35 Billion |
| Compound Annual Growth Rate | 6.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 30 |
